10x Genomics, Inc. (TXG)
TXG Stock Price Chart
Explore 10x Genomics, Inc. interactive price chart. Choose custom timeframes to analyze TXG price movements and trends.
TXG Company Profile
Discover essential business fundamentals and corporate details for 10x Genomics, Inc. (TXG) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Healthcare Information Services
IPO Date
12 Sept 2019
Employees
1.31k
Website
https://www.10xgenomics.comCEO
Serge Saxonov
Description
Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.
TXG Financial Timeline
Browse a chronological timeline of 10x Genomics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.23, while revenue estimate is $146.67m.
Earnings released on 7 May 2026
EPS came in at -$0.10 surpassing the estimated -$0.29 by +65.52%, while revenue for the quarter reached $150.84m , beating expectations by +3.03%.
Earnings released on 12 Feb 2026
EPS came in at -$0.13 surpassing the estimated -$0.19 by +31.58%, while revenue for the quarter reached $166.03m , beating expectations by +3.99%.
Earnings released on 6 Nov 2025
EPS came in at -$0.22 falling short of the estimated -$0.07 by -214.29%, while revenue for the quarter reached $149.00m , beating expectations by +4.56%.
Earnings released on 7 Aug 2025
EPS came in at $0.28 surpassing the estimated -$0.35 by +180.00%, while revenue for the quarter reached $172.91m , beating expectations by +23.94%.
Earnings released on 8 May 2025
EPS came in at -$0.36 surpassing the estimated -$0.45 by +20.00%, while revenue for the quarter reached $154.88m , beating expectations by +6.62%.
Earnings released on 12 Feb 2025
EPS came in at -$0.40 falling short of the estimated -$0.29 by -37.93%, while revenue for the quarter reached $165.02m , beating expectations by +0.02%.
Earnings released on 29 Oct 2024
EPS came in at -$0.30 surpassing the estimated -$0.34 by +11.76%, while revenue for the quarter reached $151.65m , missing expectations by -1.09%.
Earnings released on 8 Aug 2024
EPS came in at -$0.32 surpassing the estimated -$0.47 by +31.91%, while revenue for the quarter reached $153.10m , beating expectations by +2.01%.
Earnings released on 30 Apr 2024
EPS came in at -$0.50 falling short of the estimated -$0.46 by -8.70%, while revenue for the quarter reached $141.01m , missing expectations by -0.87%.
Earnings released on 15 Feb 2024
EPS came in at -$0.41 falling short of the estimated -$0.36 by -13.89%, while revenue for the quarter reached $183.98m , beating expectations by +0.64%.
Earnings released on 2 Nov 2023
EPS came in at -$0.51 falling short of the estimated -$0.45 by -13.33%, while revenue for the quarter reached $153.64m , beating expectations by +1.58%.
Earnings released on 3 Aug 2023
EPS came in at -$0.53 falling short of the estimated -$0.39 by -35.90%, while revenue for the quarter reached $146.82m , beating expectations by +4.90%.
Earnings released on 3 May 2023
EPS came in at -$0.44 falling short of the estimated -$0.38 by -15.79%, while revenue for the quarter reached $134.29m , missing expectations by -3.22%.
Earnings released on 15 Feb 2023
EPS came in at -$0.15 surpassing the estimated -$0.29 by +48.28%, while revenue for the quarter reached $156.23m , beating expectations by +5.44%.
Earnings released on 2 Nov 2022
EPS came in at -$0.37 surpassing the estimated -$0.45 by +17.78%, while revenue for the quarter reached $131.07m , beating expectations by +1.63%.
Earnings released on 8 Aug 2022
EPS came in at -$0.57 falling short of the estimated -$0.40 by -42.50%, while revenue for the quarter reached $114.61m , missing expectations by -0.95%.
Earnings released on 4 May 2022
EPS came in at -$0.38 falling short of the estimated -$0.37 by -2.70%, while revenue for the quarter reached $114.50m , beating expectations by +1.10%.
Earnings released on 16 Feb 2022
EPS came in at -$0.16 falling short of the estimated -$0.06 by -166.67%, while revenue for the quarter reached $143.53m , missing expectations by -3.37%.
Earnings released on 3 Nov 2021
EPS came in at -$0.15 surpassing the estimated -$0.18 by +16.67%, while revenue for the quarter reached $125.30m , missing expectations by -14.29%.
Earnings released on 4 Aug 2021
EPS came in at -$0.10 surpassing the estimated -$0.26 by +61.54%, while revenue for the quarter reached $115.84m , beating expectations by +2.65%.
TXG Stock Performance
Access detailed TXG performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
